Mechanistic studies showed that the axis of METTL5‐ATF4‐SLC7A11/SLC3A2 modulates tumor sensitivity to T cell‐mediated antitumor immune activity in ovarian cancers. This evidence concerns the gene SLC3A2 and ovarian carcinoma.